Search results

7 results for Belimumab

Sorted by Relevance . Sort by Date

  1. Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA397)

    Evidence-based recommendations on belimumab (Benlysta) as an add-on treatment for active autoantibody-positive systemic lupus erythematosus

  2. Musculoskeletal conditions

    Everything NICE has said on musculoskeletal conditions in an interactive flowchart

  3. COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders (NG167)

    The purpose of this guideline is to maximise the safety of children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic, while protecting staff from infection. It also enables services to make the best use of NHS resources.

  4. Past appeals and decisions

    antipsychotic 24 April 2002 TA397 Systemic lupus erythematosus (active) - belimumab 18 July 2012 TA272 Transitional cell carcinoma of...

  5. Block scoping reports

    This information helps ministers to decide whether or not a technology should be formally referred to NICE for appraisal and whether it should be referred as an MTA or an STA.